29 July 2024
29 July 2024
The integration of LumiraDx's technology into Roche's operations will introduce a multi-assay point-of-care platform.
The Series A financing was led by iGan Partners and included Topcon Healthcare and Eli Lilly and Company.
The fully automated Lumipulse G GFAP assay is set to be released in Japan, Europe, and other regions as of September 2024.
The company has published data showing that its PrecivityAD2 blood test can be used to screen for Alzheimer's disease in primary and secondary care settings.
The 57-year-old man was implanted with the artificial heart at the Texas Heart Institute as part of an FDA early feasibility study.
The study revealed that blood tests can accurately detect Alzheimer's, potentially replacing PET scans.
Daniel Lischinsky, CEO, at Ohh-Med explores the alternative treatments available for treating ED, including radiofrequency (RF) and shockwave technologies.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
